UY31418A1 - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos - Google Patents
Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivosInfo
- Publication number
- UY31418A1 UY31418A1 UY31418A UY31418A UY31418A1 UY 31418 A1 UY31418 A1 UY 31418A1 UY 31418 A UY31418 A UY 31418A UY 31418 A UY31418 A UY 31418A UY 31418 A1 UY31418 A1 UY 31418A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- treatment
- cognitive disorders
- patients affected
- human albumin
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invencion se basa en la utilizacion de albumina humana terapéutica para la preparacion de un medicamento par el tratamiento de pacientes afectados por desordenes cognitivos, en la que el modelo de administracion del medicamento comprende la administracion al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albumina terapéutica humana mediante recambio plasmático y/o perfusion intravenosa, sin dependencia del contenido de AB(Beta) en sangre del paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31418A1 true UY31418A1 (es) | 2009-05-29 |
Family
ID=40583637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31418A UY31418A1 (es) | 2007-10-26 | 2008-10-23 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos |
Country Status (17)
Country | Link |
---|---|
US (1) | US7851446B2 (es) |
EP (1) | EP2111868B1 (es) |
JP (1) | JP5437619B2 (es) |
CN (1) | CN101417123B (es) |
AR (1) | AR068901A1 (es) |
AU (1) | AU2008233025B8 (es) |
BR (1) | BRPI0804623B8 (es) |
CA (1) | CA2641830C (es) |
CL (1) | CL2008003133A1 (es) |
ES (2) | ES2332846B1 (es) |
HK (1) | HK1126689A1 (es) |
MX (1) | MX2008013635A (es) |
NZ (1) | NZ572131A (es) |
PL (1) | PL2111868T3 (es) |
PT (1) | PT2111868E (es) |
RU (1) | RU2414925C2 (es) |
UY (1) | UY31418A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5843345B2 (ja) | 2010-07-08 | 2016-01-13 | 旭化成メディカル株式会社 | β−アミロイド除去システム |
UA126232C2 (uk) * | 2016-08-18 | 2022-09-07 | Алкахест, Інк. | Спосіб лікування когнітивного розладу, пов'язаного зі старінням, та набір, що містить фракцію плазми крові |
EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
CA3061194A1 (en) * | 2017-04-26 | 2018-11-01 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
WO2020018343A1 (en) * | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
AU2019364271A1 (en) | 2018-10-26 | 2021-06-03 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
IL307764A (en) * | 2021-04-30 | 2023-12-01 | Grifols Worldwide Operations Ltd | Use of plasma exchange and low volume plasma exchange to treat cognitive impairment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3612137A1 (de) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
US7695903B2 (en) | 2000-05-23 | 2010-04-13 | The University Of Southern California | Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system |
EP1370240A4 (en) * | 2001-03-02 | 2004-09-22 | Neuron Therapeutics Inc | NEUROPROTECTOR FORMULATIONS AND METHOD |
WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
MXPA05003607A (es) | 2002-10-04 | 2005-11-17 | Prana Biotechnology Ltd | Compuestos neurologicamente activos. |
WO2004056318A2 (en) * | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
PT1592439E (pt) | 2003-02-13 | 2007-06-22 | Octapharma Ag | Processo para a preparação de uma solução de albumina |
EP1651195A4 (en) | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
-
2009
- 2009-07-02 HK HK09105923.2A patent/HK1126689A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0804623B1 (pt) | 2020-02-11 |
ES2428698T3 (es) | 2013-11-08 |
MX2008013635A (es) | 2009-05-11 |
CA2641830A1 (en) | 2009-04-26 |
EP2111868B1 (en) | 2013-08-21 |
US7851446B2 (en) | 2010-12-14 |
BRPI0804623B8 (pt) | 2021-05-25 |
ES2332846B1 (es) | 2010-07-08 |
JP2009108059A (ja) | 2009-05-21 |
PL2111868T3 (pl) | 2014-01-31 |
EP2111868A1 (en) | 2009-10-28 |
AU2008233025B2 (en) | 2013-06-27 |
RU2008141076A (ru) | 2010-04-27 |
JP5437619B2 (ja) | 2014-03-12 |
AU2008233025B8 (en) | 2013-07-25 |
RU2414925C2 (ru) | 2011-03-27 |
CN101417123A (zh) | 2009-04-29 |
AR068901A1 (es) | 2009-12-16 |
ES2332846A1 (es) | 2010-02-12 |
CN101417123B (zh) | 2012-06-27 |
HK1126689A1 (en) | 2009-09-11 |
CL2008003133A1 (es) | 2009-08-07 |
AU2008233025A1 (en) | 2009-05-14 |
PT2111868E (pt) | 2013-10-17 |
NZ572131A (en) | 2010-06-25 |
US20090111740A1 (en) | 2009-04-30 |
BRPI0804623A2 (pt) | 2009-06-30 |
CA2641830C (en) | 2013-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31418A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
JP2013155188A5 (es) | ||
AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
JP2010518164A5 (es) | ||
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
EP2424536A4 (en) | NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION | |
ECSP077843A (es) | Tratamiento o prevención del prurito | |
AR041891A1 (es) | Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza | |
Nordal | Where has all the psychotherapy gone? | |
EA201170319A1 (ru) | Приложение напряжения сдвига для лечения заболеваний | |
CN114588164A (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
Periyasami et al. | Attai Vidal (Leech Therapy) in Siddha System of Medicine and their current concept in therapeutic application-A Review | |
Cohen et al. | Mebaral in the treatment of epilepsy | |
Patel et al. | Management of Non Healing Ulcer with Local Application of Yastimadhu Ghrita (Glycyrrhiza Glabra L.): A Single Case Study | |
JP1720531S (ja) | 薬液投与器用穿刺具 | |
Boroojeny et al. | Effects of oral clonidine as pre-medication on blood pressure in patients under spinal anesthesia | |
Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
JP1720529S (ja) | 薬液投与器用穿刺具 | |
CN202105157U (zh) | 一种新型内科用外敷中药治疗装置 | |
Van Schoor | Colds, flu and coughing: a review of over-the-counter nasal therapies in general practice | |
JP2016504361A5 (es) | ||
CN2605869Y (zh) | 冠心病外用药物护胸袋 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190715 |